Evotec and Vi­for launch joint kid­ney dis­ease ven­ture

Two years af­ter they be­gan col­lect­ing and an­a­lyz­ing da­ta from kid­ney banks across the UK, Evotec has launched a joint ven­ture with Vi­for to build new ther­a­pies off of those da­ta.

The project is 50:50, the com­pa­nies said, but will launch with a €25 mil­lion ($27.7 mil­lion) in­jec­tion from Vi­for, the Ga­len­cia spin­off. Clin­i­cal and com­mer­cial costs of any po­ten­tial ther­a­pies that emerge from the part­ner­ship will be split even­ly be­tween the two com­pa­nies, with var­i­ous opt-out rights from a pre­de­ter­mined prof­it shar­ing agree­ment. Any drugs that get out of the clin­ic will be out­li­censed to Vi­for for reg­is­tra­tion and com­mer­cial­iza­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER